Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604383 · ClinicalTrials.gov registry record · Phase 3
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
A Phase 3 study, sponsored by Chromaderm.
- Completed
- Registry status
- Phase 3
- Development phase
- 685
- Enrollment target
NCT00604383 is a Phase 3 study that has completed, run by Chromaderm. The registered enrollment target is 685 participants.
The verdict
NCT00604383, a Phase 3 study, has completed, sponsored by Chromaderm.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 685 participants
- Enrollment target
Study Summary
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
Interventions
- DRUG placebo
- DRUG ruboxistaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 685 participants |
| Start Date | 2001-03 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00604383
The ClinicalTrials.gov registry entry for NCT00604383 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 685 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chromaderm, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00604383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00604383 about?
NCT00604383 is a clinical study titled "Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study". This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
What is the current status of trial NCT00604383?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 685 participants. The study started on 2001-03. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00604383?
The interventions under investigation include: placebo (DRUG), ruboxistaurin (DRUG).
Who is sponsoring clinical trial NCT00604383?
This trial is sponsored by Chromaderm, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.